Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Veracyte Inc (VCYT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 946,740
  • Shares Outstanding, K 41,109
  • Annual Sales, $ 92,010 K
  • Annual Income, $ -23,000 K
  • 60-Month Beta 1.03
  • Price/Sales 10.25
  • Price/Cash Flow N/A
  • Price/Book 11.65

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.07
  • Number of Estimates 3
  • High Estimate -0.02
  • Low Estimate -0.12
  • Prior Year -0.27
  • Growth Rate Est. (year over year) +74.07%

Price Performance

See More
Period Period Low Period High Performance
1-Month
21.50 +7.12%
on 03/19/19
26.75 -13.91%
on 04/08/19
+1.18 (+5.40%)
since 03/18/19
3-Month
16.88 +36.43%
on 01/25/19
26.75 -13.91%
on 04/08/19
+5.75 (+33.28%)
since 01/18/19
52-Week
5.50 +318.73%
on 04/19/18
26.75 -13.91%
on 04/08/19
+17.39 (+308.33%)
since 04/18/18

Most Recent Stories

More News
Veracyte Announces Publication Highlighting Afirma GSC's Ability to Rule Out Cancer in Challenging Thyroid Nodule Subtype

Veracyte, Inc. announced today that a new study published online in BMC Systems Biology showcases the development of the Afirma(R) Genomic Sequencing Classifier (GSC) and its ability...

VCYT : 23.03 (+0.44%)
Relatively Good Performance Detected in Shares of Veracyte Inc in the Biotechnology Industry (VCYT , LXRX , BCRX , DVAX , KPTI )

Below are the top five companies in the Biotechnology industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have the...

VCYT : 23.03 (+0.44%)
LXRX : 5.58 (-1.41%)
BCRX : 7.92 (+2.99%)
Veracyte to Release First Quarter 2019 Financial Results on April 30, 2019

Veracyte, Inc. (Nasdaq: VCYT) today announced that it will release its financial results for the first quarter 2019 after the close of market on Tuesday, April 30, 2019. Company management...

VCYT : 23.03 (+0.44%)
73.0% Return Seen to Date on SmarTrend Veracyte Inc Call (VCYT)

SmarTrend identified an Uptrend for Veracyte Inc (NASDAQ:VCYT) on January 4th, 2019 at $14.02. In approximately 3 months, Veracyte Inc has returned 73.04% as of today's recent price of $24.26.

VCYT : 23.03 (+0.44%)
Veracyte Announces Data Published in The Lancet Respiratory Medicine Demonstrate that the Envisia Genomic Classifier Improves Diagnosis of IPF

Veracyte, Inc. announced that data published online today in The Lancet Respiratory Medicine suggest that use of the company's Envisia Genomic Classifier improves diagnosis for patients...

VCYT : 23.03 (+0.44%)
Best Relative Performance in the Biotechnology Industry Detected in Shares of Natera Inc (NTRA , ATRA , VCYT , ALKS , ALNY )

We looked at the Biotechnology industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look at...

VCYT : 23.03 (+0.44%)
NTRA : 18.54 (-3.99%)
ATRA : 31.86 (-2.21%)
Veracyte Announces Participation in the 18th Annual Needham Healthcare Conference

Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, today announced that Bonnie H. Anderson, chairman and chief executive officer, is scheduled to present at the...

VCYT : 23.03 (+0.44%)
Research Report Identifies Alamos Gold, Thermo Fisher Scientific, Veracyte, Air Lease, Carlisle Companies, and Medidata Solutions with Renewed Outlook -- Fundamental Analysis, Calculating Forward Movement

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Alamos Gold Inc. (NYSE:AGI),...

VCYT : 23.03 (+0.44%)
AGI : 4.70 (-1.26%)
TMO : 259.78 (+0.88%)
MDSO : 78.87 (+3.49%)
AL : 37.80 (-0.53%)
CSL : 127.93 (+0.84%)
Veracyte Inc Rises 1.05% on Heavy Volume: Watch For Potential Pullback

Veracyte Inc (NASDAQ:VCYT) traded in a range yesterday that spanned from a low of $25.36 to a high of $26.03. Yesterday, the shares gained 1.0%, which took the trading range above the 3-day high of $25.55...

VCYT : 23.03 (+0.44%)
Shares of Chemocentryx Inc Rank the Highest in Terms of Relative Performance in the Biotechnology Industry (CCXI , VCYT , AIMT , MGNX , MRTX)

We looked at the Biotechnology industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look at...

VCYT : 23.03 (+0.44%)
AIMT : 20.21 (-0.93%)
MRTX : 63.27 (+1.67%)
CCXI : 12.13 (-1.30%)

Barchart Technical Opinion

The Barchart Opinion rating is a Hold. Short term, the outlook is Falling.

See More Share

Trade VCYT with:

Business Summary

Veracyte, Inc. is a diagnostics company. It is focused on discovering, developing and commercializing molecular cytology solutions. The Company provides Afirma Thyroid FNA Analysis, which helps physicians in reducing unnecessary diagnostic surgeries for patients with thyroid nodules. Veracyte is also...

See More

Key Turning Points

2nd Resistance Point 24.01
1st Resistance Point 23.52
Last Price 23.03
1st Support Level 22.56
2nd Support Level 22.09

See More

52-Week High 26.75
Last Price 23.03
Fibonacci 61.8% 18.63
Fibonacci 50% 16.13
Fibonacci 38.2% 13.62
52-Week Low 5.50

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar